GlassScriptPhysician profile
Matthew D Evans
NPI 1821431560
$2,092.04
in general payments reported to CMS, 2019-2025
23 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2022: $42.39 · 2023: $764 · 2024: $583 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.74 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.64 | 2022-2025 | |
| Braeburn INC. | $198.91 | 2024-2025 | Brixadi |
| Indivior INC. | $182.18 | 2023-2025 | Sublocade |
| Novo Nordisk INC | $166.42 | 2019 | |
| Alkermes, INC. | $147.31 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $140.50 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $137.14 | 2019-2024 | Invega Sustenna, Invega |
| Atricure, INC. | $128.82 | 2019 | |
| Organon LLC | $111.69 | 2023 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $108.03 | 2019 | |
| Gilead Sciences, INC. | $91.95 | 2023-2025 | Epclusa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.96 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.64 | 2023 | |
| Uswm, LLC | $32.52 | 2023 | Zimhi, Lucemyra |
| Pfizer INC. | $28.69 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.96 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $16.54 | 2019 | |
| Impulse Dynamics (USA) INC. | $16.13 | 2023 | Optimizer |
| Qiagen, LLC | $13.71 | 2022 | |
| Lilly USA, LLC | $12.72 | 2023 | Jardiance |
| Boston Scientific Corporation | $11.35 | 2019 | |
| Daiichi Sankyo INC. | $11.17 | 2019 | |
| Amgen INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.